Enkephalin Or Derivative Affecting Or Utilizing Patents (Class 514/18.5)
  • Patent number: 9895438
    Abstract: The present invention provides novel therapeutic applications of low dose naltrexone (LDN). Said applications have been determined in light of the discovery by the present inventors that naltrexone acts as an antagonist of Toll-like receptor 9 (TLR9), an innate immune receptor which elicits the production of inflammatory cytokines when agonized. Chronic inflammation and TLR9 overexpression are characteristics of a number of disorders, including certain cancers. Accordingly, the present invention provides novel uses of naltrexone in the treatment of a subject having a disorder characterized by TLR9 overexpression and/or overactivity of TLR9-mediated signalling. The present invention also provides novel uses of naltrexone in the supportive care of subject having a tumor/cancer, and methods of treating and providing supportive care to a subject, comprising the administration of naltrexone.
    Type: Grant
    Filed: May 12, 2014
    Date of Patent: February 20, 2018
    Assignee: Cancer Vaccine Institute
    Inventors: Angus Dalgleish, Rachel Allen
  • Patent number: 9375458
    Abstract: The present invention relates to pharmaceutical compositions for treating neoplasias in an animal or human comprised of a carrier and therapeutically effective amounts of at least one chemotherapeutic agent along with the biotherapeutic endogenous pentapeptide Met-enkephalin, referred to as opioid growth factor. Also provided are methods of treating neoplasias in an animal or human in need of such treatment, comprising the administration to the animal or human therapeutically effective amounts of a pharmaceutical composition comprised of a carrier and therapeutically effective amounts of at least one neoplasia-treating agent, such as a chemotherapeutic agent or radiation, along with opioid growth factor.
    Type: Grant
    Filed: October 25, 2012
    Date of Patent: June 28, 2016
    Assignee: The Penn State Research Foundation
    Inventors: Ian S. Zagon, Patricia J. McLaughlin, Jill P. Smith
  • Patent number: 8957025
    Abstract: The present invention relates to dipeptide enkephalin analogues of Formula (I) and their tautomers, ionic forms and pharmaceutically acceptable salts, and their use in medicine, in particular as opioid agonists.
    Type: Grant
    Filed: June 29, 2012
    Date of Patent: February 17, 2015
    Assignee: Pfizer Inc.
    Inventor: Dafydd Rhys Owen
  • Patent number: 8920819
    Abstract: Compositions comprising a lipophilic derivative of a hydrophilic drug and an amphiphile compound for use in therapy of the human or animal body are provided. Methods of medical treatment, wherein a composition according to the invention is administered to a human or animal body also form part of the invention. It is preferred that the drug is delivered to the brain.
    Type: Grant
    Filed: August 31, 2012
    Date of Patent: December 30, 2014
    Assignee: University College London
    Inventors: Ijeoma Uchegbu, Aikaterini Lalatsa, Andreas Schatzlein
  • Patent number: 8685955
    Abstract: Novel iron chelators exhibiting neuroprotective and good transport properties are useful in iron chelation therapy for treatment of a disease, disorder or condition associated with iron overload and oxidative stress, e.g., a neurodegenerative or cerebrovascular disease or disorder, a neoplastic disease, hemochromatosis, thalassemia, a cardiovascular disease, diabetes, an inflammatory disorder, anthracycline cardiotoxicity, a viral infection, a protozoal infection, a yeast infection, retarding aging, and prevention and/or treatment of skin aging and skin protection against sunlight and/or UV light. The iron chelator function is provided by a 8-hydroxyquinoline, a hydroxypyridinone or a hydroxamate moiety. The neuroprotective function is imparted to the compound, e.g., by a neuroprotective peptide. A combined antiapoptotic and neuroprotective function is provided by a propargyl group.
    Type: Grant
    Filed: November 14, 2011
    Date of Patent: April 1, 2014
    Assignees: Technion Research and Development Foundation Ltd., Yeda Research and Development Co. Ltd.
    Inventors: Moussa B. H. Youdim, Matitiyahu Fridkin, Hailin Zheng, Rivka Warshawsky
  • Publication number: 20140011745
    Abstract: The present invention relates to a method for reducing electrical disturbance of a cell's resting membrane potential comprising administering an effective amount of a composition comprising an effective amount of a local anaesthetic and of one or more of a potassium channel opener, an adenosine receptor agonist, an anti-adrenergic, a calcium antagonist, an opioid, an NO donor and a sodium hydrogen exchange inhibitor.
    Type: Application
    Filed: July 5, 2013
    Publication date: January 9, 2014
    Applicant: Hibernation Therapeutics Limited
    Inventor: Geoffrey Phillip Dobson
  • Patent number: 8529928
    Abstract: Biodegradable polymers incorporating biomolecules and methods of their use are provided. Certain aspects provide biomolecules crosslinked with diglycidyl esters. The disclosed compositions have numerous applications including cellular regeneration, wound healing, and cellular differentiation.
    Type: Grant
    Filed: July 6, 2007
    Date of Patent: September 10, 2013
    Assignee: Georgia Tech Research Corporation
    Inventors: Yadong Wang, Blaine Zern, Christiane Gumera
  • Patent number: 8440623
    Abstract: A substantially hydrophilic conjugate is provided having a peptide that is capable of passing the blood-brain barrier covalently linked to a water-soluble nonpeptidic polymer such as polyethylene glycol. The conjugate exhibits improved solubility and in vivo stability and is capable of passing the blood-brain barrier of an animal.
    Type: Grant
    Filed: June 28, 2011
    Date of Patent: May 14, 2013
    Assignee: Nektar Therapeutics
    Inventors: Michael David Bentley, Michael James Roberts
  • Publication number: 20130053326
    Abstract: Compositions and methods for treatment of sexual dysfunctions by administering to a subject a pharmaceutical composition comprising a delta opioid receptor agonist in an amount effective to delay the onset of ejaculation in the subject during sexual stimulation.
    Type: Application
    Filed: January 2, 2003
    Publication date: February 28, 2013
    Inventors: Kwen-Jen Chang, Klim King, Kestutis P. Biciunas, Robert W. McNutt, JR., William Pendergast, Shyi-Tai Jan
  • Publication number: 20130034590
    Abstract: Compositions comprising a lipophilic derivative of a hydrophilic drug and an amphiphile compound for use in therapy of the human or animal body are provided. Methods of medical treatment, wherein a composition according to the invention is administered to a human or animal body also form part of the invention. It is preferred that the drug is delivered to the brain.
    Type: Application
    Filed: August 31, 2012
    Publication date: February 7, 2013
    Inventors: Ijeoma Uchegbu, Aikaterini Lalatsa, Andreas Schatzlein
  • Publication number: 20120258176
    Abstract: The invention discloses particulate complexes composed of chitosan, poly-glutamic acid, and at least one bioactive agent, wherein equal moles of the positively charged chitosan and the negatively charged poly-glutamic acid substrate form an electrostatic network enabling improved loading the bioactive agent.
    Type: Application
    Filed: May 7, 2012
    Publication date: October 11, 2012
    Inventors: Hsing-Wen Sung, Zi-Xian Liao, Shu-Fen Peng, Hosheng Tu
  • Patent number: 8278277
    Abstract: Compositions comprising a lipophilic derivative of a hydrophilic drug and an amphiphile compound for use in therapy of the human or animal body are provided. Methods of medical treatment, wherein a composition according to the invention is administered to a human or animal body also form part of the invention. It is preferred that the drug is delivered to the brain.
    Type: Grant
    Filed: April 9, 2009
    Date of Patent: October 2, 2012
    Assignee: University College London
    Inventors: Ijeoma Uchegbu, Aikaterini Lalatsa, Andreas Schatzlein
  • Patent number: 8268821
    Abstract: The present invention relates generally to the field of pain management, and in particular, the management of neuropathic or inflammatory pain including a neuropathic or inflammatory component of nociceptive pain. More particularly, the present invention provides methods and compositions which treat, alleviate, prevent, diminish or otherwise ameliorate the symptoms of neuropathic or inflammatory pain. The present invention further contemplates combination therapy involved in the treatment of pain in association with the treatment of a particular disease condition or pathology. The present invention further also provides sustained and slow release formulations, tamper-proof deliver systems and stents, catheters and other mechanical devices coated with formulations which permit sustained or slow release of active ingredients involved in pain management.
    Type: Grant
    Filed: December 1, 2010
    Date of Patent: September 18, 2012
    Assignee: Relevare Aust. Pty Ltd
    Inventors: Raymond Nadeson, Adam Paul Tucker, Colin Goodchild
  • Publication number: 20120058945
    Abstract: Novel iron chelators exhibiting neuroprotective and good transport properties are useful in iron chelation therapy for treatment of a disease, disorder or condition associated with iron overload and oxidative stress, e.g., a neurodegenerative or cerebrovascular disease or disorder, a neoplastic disease, hemochromatosis, thalassemia, a cardiovascular disease, diabetes, an inflammatory disorder, anthracycline cardiotoxicity, a viral infection, a protozoal infection, a yeast infection, retarding aging, and prevention and/or treatment of skin aging and skin protection against sunlight and/or UV light. The iron chelator function is provided by a 8-hydroxyquinoline, a hydroxypyridinone or a hydroxamate moiety. The neuroprotective function is imparted to the compound, e.g., by a neuroprotective peptide. A combined antiapoptotic and neuroprotective function is provided by a propargyl group.
    Type: Application
    Filed: November 14, 2011
    Publication date: March 8, 2012
    Applicants: Yeda Research and Development Co., Ltd., Technion Research and Development Foundation Ltd.
    Inventors: MOUSSA YOUDIM, Matitiyahu Fridkin, Hailin Zheng, Abraham Warshawsky, Rivka Warshawsky
  • Patent number: 8080519
    Abstract: Pharmaceutical agents, compositions containing the same and methods for their use for enhancing the bioavailability and pharmacological efficacy of therapeutic peptides. The pharmaceutical agents have the formula Carrier-Linker-Peptide Wherein Peptide is a therapeutically active peptide species having the formula aan wherein n is the number of amino acid residues in the peptide and n is 2 to 40, Carrier is benzoyl, phenylacetyl, cinnamoyl, 3-OH-cinnamoyl, 3,4-OH-cinnamoyl, 3,4-dimethoxycinnamoyl, 3,4-methylenedioxycinnamoyl, 3-methoxycinnamoyl, 3,4-diethoxy-cinnamoyl, 3,4,5-trimethoxy-cinnamoyl, t-butoxycarbonyl, benzyloxycarbonyl, pivaloyl, N-9-fluorenylmethoxycarbonyl, fumaroyl and derivatives thereof and Linker is a C6 to C16 lipidic chain or a derivative thereof, an 8-amino-3,6-dioxaoctanoic acid or polymeric derivative thereof, pseudo peptide, or peptide mimic. Methods of use of compositions having the formula Carrier-Peptide wherein Carrier and Peptide are as just defined are also disclosed.
    Type: Grant
    Filed: January 15, 2010
    Date of Patent: December 20, 2011
    Assignee: ImmuPharma SA (France)
    Inventor: Robert H. Zimmer
  • Publication number: 20110250212
    Abstract: The present invention relates to methods for the treatment or prevention of trigeminal nerve-associated pain, in particular chronic, acute and procedural-related pain. The methods comprise administration of analgesic agents to the trigeminal nerve system which results in analgesia to the facial or head region.
    Type: Application
    Filed: June 21, 2011
    Publication date: October 13, 2011
    Inventors: David C. YEOMANS, William H. FREY, II, Daniel I. JACOBS
  • Publication number: 20100303901
    Abstract: Enteric coated capsules or tablets for oral delivery of a protein, polypeptide or peptide drug, in particular for oral delivery of insulin, are provided, comprising microparticles of the protein, polypeptide or peptide drug, microparticles of a protease inhibitor and, optionally, microparticles of an absorption enhancer. The protease inhibitor and the absorption enhancer may be together in the same microparticles. The microparticles of each component are embedded in an enteric polymer matrix.
    Type: Application
    Filed: April 27, 2008
    Publication date: December 2, 2010
    Inventors: Eyal Shimoni, Ory Ramon, Isaiah J. Kopelman, Shimon Mizrahi, Nir Salzmann, Yaakov Nahmias, Aharon Oren
  • Publication number: 20100297066
    Abstract: Novel biodegradable compositions are disclosed. The biodegradable compositions include at least one hydroxyl-terminated component and at least one bioactive peptide in a linear chain. The compositions may be utilized as medical devices including drug delivery devices, tissue adhesives and/or sealants.
    Type: Application
    Filed: May 14, 2008
    Publication date: November 25, 2010
    Inventors: Joshua B. Stopek, Brian Cuevas
  • Publication number: 20100292158
    Abstract: Pharmaceutical agents, compositions containing the same and methods for their use for enhancing the bioavailability and pharmacological efficacy of therapeutic peptides. The pharmaceutical agents have the formula Carrier-Linker-Peptide Wherein Peptide is a therapeutically active peptide species having the formula aan wherein n is the number of amino acid residues in the peptide and n is 2 to 40, Carrier is benzoyl, phenylacetyl, cinnamoyl, 3-OH-cinnamoyl, 3,4-OH-cinnamoyl, 3,4-dimethoxycinnamoyl, 3,4-methylenedioxycinnamoyl, 3-methoxycinnamoyl, 3,4-diethoxy-cinnamoyl, 3,4,5-trimethoxy-cinnamoyl, t-butoxycarbonyl, benzyloxycarbonyl, pivaloyl, N-9-fluorenylmethoxycarbonyl, fumaroyl and derivatives thereof and Linker is a C6 to C16 lipidic chain or a derivative thereof, an 8-amino-3,6-dioxaoctanoic acid or polymeric derivative thereof, pseudo peptide, or peptide mimic. Methods of use of compositions having the formula Carrier-Peptide wherein Carrier and Peptide are as just defined are also disclosed.
    Type: Application
    Filed: January 15, 2010
    Publication date: November 18, 2010
    Inventor: ROBERT H. ZIMMER